Cargando…

The mechanism of anti-tumor immunity induced by varlilumab, a CD27 agonist mAb, is model dependent

Detalles Bibliográficos
Autores principales:	He, Li-Zhen, Wasiuk, Anna, Testa, James, Weidlick, Jeffrey, Sisson, Crsytal, Crocker, Andrea, Widger, Jenifer, Forsberg, Eirc, Gergel, Lauren, Thomas, Lawrence, Marsh, Henry, Keler, Tibor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649460/ http://dx.doi.org/10.1186/2051-1426-3-S2-P188

Ejemplares similares

Conditioning treatment with CD27 Ab enhances expansion and antitumor activity of adoptively transferred T cells in mice
por: Wasiuk, Anna, et al.
Publicado: (2021)

Combination therapies augment the anti-tumor activity of agonist CD27 mAb in human CD27 transgenic mouse models
por: He, Li-Zhen, et al.
Publicado: (2013)

Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab
por: Ramakrishna, Venky, et al.
Publicado: (2015)

Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy
por: Vitale, Laura A., et al.
Publicado: (2020)

Toll-like receptor agonists shape the immune responses to a mannose receptor-targeted cancer vaccine
por: He, Li-Zhen, et al.
Publicado: (2015)

Immune correlates of Varlilumab treated cancer patients are consistent with CD27 costimulatory activity
por: Bullock, Timothy, et al.
Publicado: (2014)

Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors
por: Sanborn, Rachel E, et al.
Publicado: (2022)

Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity
por: Thomas, Lawrence J, et al.
Publicado: (2014)

Production and N-glycan engineering of Varlilumab in Nicotiana benthamiana
por: Nguyen, Kim Dua, et al.
Publicado: (2023)

SEPPA-mAb: spatial epitope prediction of protein antigens for mAbs
por: Qiu, Tianyi, et al.
Publicado: (2023)

FcγR requirements and costimulatory capacity of Urelumab, Utomilumab, and Varlilumab
por: Leitner, Judith, et al.
Publicado: (2023)

Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs
por: Fusco, Marnie L., et al.
Publicado: (2015)

The Different Colors of mAbs in Solution
por: Ambrogelly, Alexandre
Publicado: (2021)

Correction: Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs
por: Fusco, Marnie L., et al.
Publicado: (2015)

Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb
por: Bolaños-Mateo, Elixabet, et al.
Publicado: (2014)

Cellular tools for biosimilar mAb analysis
por: Lindemann, Carsten, et al.
Publicado: (2013)

Evolving trends in mAb production processes
por: Shukla, Abhinav A., et al.
Publicado: (2017)

State of the art in anti-cancer mAbs
por: Chiavenna, S. M., et al.
Publicado: (2017)

Stability enhancement in a mAb and Fab coformulation
por: Zhang, Hongyu, et al.
Publicado: (2020)

Pan-sarbecovirus mAb protects from variants
por: Flemming, Alexandra
Publicado: (2021)

A mAb for the detection of the antiretroviral drug emtricitabine
por: Youngpairoj, Ae S., et al.
Publicado: (2022)

Combining NK cells and mAb9.2.27 to combat NG2-dependent and anti-inflammatory signals in glioblastoma
por: Kmiecik, Justyna, et al.
Publicado: (2014)

Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment
por: Turaj, Anna H., et al.
Publicado: (2017)

Novel strategy for a high-yielding mAb-producing CHO strain (overexpression of non-coding RNA enhanced proliferation and improved mAb yield)
por: Tabuchi, Hisahiro
Publicado: (2013)

A novel human mAb (MERS-GD27) provides prophylactic and postexposure efficacy in MERS-CoV susceptible mice
por: Niu, Peihua, et al.
Publicado: (2018)

Developmental changes in heparan sulfate expression: in situ detection with mAbs
Publicado: (1992)

Direct analysis of mAb aggregates in mammalian cell culture supernatant
por: Paul, Albert J, et al.
Publicado: (2014)

Conservancy of mAb Epitopes in Ebolavirus Glycoproteins of Previous and 2014 Outbreaks
por: Ponomarenko, Julia, et al.
Publicado: (2014)

Self-Interaction Chromatography of mAbs: Accurate Measurement of Dead Volumes
por: Hedberg, S. H. M., et al.
Publicado: (2015)

Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma
por: Kroesen, Michiel, et al.
Publicado: (2016)

Germinality does not necessarily define mAb expression and thermal stability
por: Schwaigerlehner, Linda, et al.
Publicado: (2019)

The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs
por: Golay, Josée, et al.
Publicado: (2020)

A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors
por: Burris, Howard, et al.
Publicado: (2013)

A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors
por: Ansell, Stephen, et al.
Publicado: (2013)

Endoplasmic reticulum retention motif fused to recombinant anti-cancer monoclonal antibody (mAb) CO17-1A affects mAb expression and plant stress response
por: Song, Ilchan, et al.
Publicado: (2018)

Strategies for adaptation of mAb-producing CHO cells to serum-free medium
por: Costa, A Rita, et al.
Publicado: (2011)

Successful radioimmunotherapy of established syngeneic rat colon carcinoma with (211)At-mAb
por: Eriksson, Sophie E, et al.
Publicado: (2013)

Characterization of mAb aggregates in a mammalian cell culture production process
por: Paul, Albert, et al.
Publicado: (2013)

Characterization of Two Novel mAbs Recognizing Different Epitopes on CD43
por: Kim, Soseul, et al.
Publicado: (2014)

Deamidated gluten: specific detection and characterisation with INRA-DG1 mAb
por: Tranquet, Olivier, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_jqi8og2uogj043a9oiui19vq9f